

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

**PATIENT:**

Name: .....

Ward: ..... NHI: .....

**Aflibercept**

**INITIATION – Wet Age Related Macular Degeneration**

Re-assessment required after 3 months

**Prerequisites** (tick boxes where appropriate)

- Wet age-related macular degeneration (wet AMD)
- or
- Polypoidal choroidal vasculopathy
- or
- Choroidal neovascular membrane from causes other than wet AMD

and

- The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab
- or
- There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart

and

- There is no structural damage to the central fovea of the treated eye
- and
- Patient has not previously been treated with ranibizumab or faricimab for longer than 3 months

or

- Patient has current approval to use ranibizumab or faricimab for treatment of wAMD and was found to be intolerant within 3 months
- or
- Patient has previously\* (\*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment

**CONTINUATION – Wet Age Related Macular Degeneration**

Re-assessment required after 12 months

**Prerequisites** (tick boxes where appropriate)

- Documented benefit must be demonstrated to continue
- and
- Patient's vision is 6/36 or better on the Snellen visual acuity score
- and
- There is no structural damage to the central fovea of the treated eye

**INITIATION – Diabetic Macular Oedema**

Re-assessment required after 4 months

**Prerequisites** (tick boxes where appropriate)

- Patient has centre involving diabetic macular oedema (DMO)
- and
- Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly
- and
- Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision
- and
- Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers
- and
- There is no centre-involving sub-retinal fibrosis or foveal atrophy
- and
- Patient has not previously been treated with faricimab for longer than 3 months

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

**PATIENT:**

Name: .....

Name: .....

Ward: .....

NHI: .....

**Aflibercept** - *continued*

**CONTINUATION – Diabetic Macular Oedema**

Re-assessment required after 12 months

**Prerequisites** (tick boxes where appropriate)

- There is stability or two lines of Snellen visual acuity gain
- and  There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid)
- and  Patient's vision is 6/36 or better on the Snellen visual acuity score
- and  There is no centre-involving sub-retinal fibrosis or foveal atrophy

I confirm that the above details are correct:

Signed: ..... Date: .....